<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671901</url>
  </required_header>
  <id_info>
    <org_study_id>20-467</org_study_id>
    <nct_id>NCT04671901</nct_id>
  </id_info>
  <brief_title>A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors</brief_title>
  <official_title>A Single Arm Open-Label Pilot Study of Prophylactic Romiplostim Use Compared to Benchmark Rate in the Prevention of Chemotherapy Induced Thrombocytopenia in Pediatric Solid Tumors Patients Undergoing Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether romiplostim can help prevent low platelet&#xD;
      counts caused by N8 or EFT chemotherapy, reduce the number of platelet transfusions required&#xD;
      during chemotherapy, and prevent treatment delays due to low platelet counts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">December 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare total number of platelet transfusions with benchmark rate after romiplostim administration.</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The primary purpose of this study is to evaluate whether romiplostim administration can decrease the total number of platelet transfusions required during the treatment courses of N8 or EFT when compared to the benchmark rate.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Solid Tumor, Childhood</condition>
  <condition>Solid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pediatric Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of N8 or EFT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <description>Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 3 mcg/kg, with subsequent doses titrated per protocol for a target of platelet count &gt; 75,000- 200,000/mcL. Participants will continue romiplostim until completion of N8 or EFT, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.</description>
    <arm_group_label>Pediatric Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of a primary solid tumor. Patients must have histological&#xD;
             verification of malignancy at MSKCC.&#xD;
&#xD;
          -  Male and female patients aged 1-21 years with a primary solid tumor undergoing&#xD;
             treatment with the pre-defined chemotherapy regimens of N8 or EFT. Prior to enrollment&#xD;
             patient could have been undergoing induction therapy with a similarly myelosuppressive&#xD;
             regimen as long as they will be continuing with N8 or EFT at the time of study&#xD;
             enrollment.&#xD;
&#xD;
        Note: Patients who received 3 prior cycles of induction chemotherapy, prior to enrollment&#xD;
        will be eligible for this study.&#xD;
&#xD;
          -  Total Bilirubin (sum of conjugated + unconjugated) ≤ 3 times institutional upper limit&#xD;
             of normal (ULN) for age and ALT/AST ≤ 3 times institutional ULN for age.&#xD;
&#xD;
          -  Normal cardiac function:&#xD;
&#xD;
               -  Shortening fraction greater than or equal to 28% by echocardiogram OR Left&#xD;
                  ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-&#xD;
                  99m pertechnetate radionuclide cineangiography (MUGA) or echocardiogram.&#xD;
&#xD;
               -  Screening ECG with corrected QT (QTc) interval of &lt; 470 msec.&#xD;
&#xD;
               -  Timing of cardiac assessment: We will utilize the most recent EKG/ECHO when&#xD;
                  assessing cardiac function. See section 9.0 for additional details.&#xD;
&#xD;
          -  Adequate renal function, defined as an estimated Creatinine Clearance or GFR &gt;40ml/min&#xD;
             or an normal creatine for age (see below)&#xD;
&#xD;
        Serum Creatinine by age:&#xD;
&#xD;
        Age (years) &lt;6: Maximum Serum Creatinine (mg/dL), Male 0.8, Female 0.8 Age (years) 6 to&#xD;
        &lt;10: Maximum Serum Creatinine (mg/dL), Male 1, Female 1 Age (years) 10 to &lt;13: Maximum&#xD;
        Serum Creatinine (mg/dL), Male 1.2, Female 1.2 Age (years) 13 to &lt;16: Maximum Serum&#xD;
        Creatinine (mg/dL), Male 1.5, Female 1.4 Age (years) &gt;16: Maximum Serum Creatinine (mg/dL),&#xD;
        Male 1.7, Female 1.4&#xD;
&#xD;
        These threshold creatine values were derived from the Scwartz formula estimating GFR,&#xD;
        utilizing child length and statured published by the CDC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of hematologic malignancies or allogenic/autogenic stem cell&#xD;
             transplant.&#xD;
&#xD;
          -  Patients with a currently known predisposition to a myeloid stem cell disorder,&#xD;
             myeloid leukemia, and/or bone marrow failure syndrome including, but not limited to:&#xD;
&#xD;
               -  Aplastic anemia&#xD;
&#xD;
               -  Ataxia telangiectasia&#xD;
&#xD;
               -  Bloom syndrome&#xD;
&#xD;
               -  Congenital amegakaryocytic thrombocytopenia&#xD;
&#xD;
               -  Cyclic neutropenia&#xD;
&#xD;
               -  Diamond Blackfan anemia&#xD;
&#xD;
               -  Dyskeratosis congenita&#xD;
&#xD;
               -  Familial AML/MDS syndromes (including ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1,&#xD;
                  SRP72)&#xD;
&#xD;
               -  Fanconi anemia&#xD;
&#xD;
               -  Kostmann disease&#xD;
&#xD;
               -  Li-Fraumeni syndrome&#xD;
&#xD;
               -  Neurofibromatosis&#xD;
&#xD;
               -  Nijmegen breakage syndrome&#xD;
&#xD;
               -  Noonan syndrome&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
               -  Pearson syndrome&#xD;
&#xD;
               -  Poland syndrome&#xD;
&#xD;
               -  Rothmund-Thomson syndrome&#xD;
&#xD;
               -  Severe congenital neutropenia&#xD;
&#xD;
               -  Thrombocytopenia absent radii syndrome&#xD;
&#xD;
               -  Trisomy 8&#xD;
&#xD;
               -  Trisomy 21&#xD;
&#xD;
               -  WHIM syndrome&#xD;
&#xD;
               -  Wiskott Aldrich syndrome&#xD;
&#xD;
               -  Xeroderma pigmentosa&#xD;
&#xD;
          -  Secondary malignancy in the past 5 years.&#xD;
&#xD;
          -  Patients who have previously undergone up-front chemotherapy and have relapsed or&#xD;
             progressed through therapy.&#xD;
&#xD;
          -  Patients who have received 4 or more cycles of induction chemotherapy for their&#xD;
             current malignancy prior to time of enrollment.&#xD;
&#xD;
          -  Previous use of romiplostim, eltrombopag, recombinant human TPO, or any other TPO&#xD;
             receptor agonist, or any investigational platelet producing agent.&#xD;
&#xD;
          -  Patients receiving other investigational agents are not eligible for study entry.&#xD;
&#xD;
        History of uncontrolled arrhythmias, clinically significant electrocardiogram (ECG)&#xD;
        abnormalities, active heart failure or pericardial disease.&#xD;
&#xD;
          -  Patients with current or prior venous thrombotic event or arterial thrombotic event at&#xD;
             time of enrollment will be ineligible for this study.&#xD;
&#xD;
          -  Pregnant women/lactating mothers.&#xD;
&#xD;
          -  Patients unwilling to use effective contraception method, which includes abstinence.&#xD;
&#xD;
          -  Patients with an inability to return for follow-up visits or obtain follow-up studies&#xD;
             required to assess toxicity to therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MIchael Ortiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Ortiz, MD</last_name>
    <phone>212-639-6057</phone>
    <email>ortizm2@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gerald Soff, MD</last_name>
    <phone>646-608-3724</phone>
    <email>soffg@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Limited Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited Protocol Activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ortiz, MD</last_name>
      <phone>212-639-6057</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>romiplostim</keyword>
  <keyword>primary solid tumor</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Solid tumor, childhood</keyword>
  <keyword>Childhood solid tumor</keyword>
  <keyword>Pediatric Solid Tumors</keyword>
  <keyword>20-467</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

